UK restricts use of puberty blockers to research purposes only.

Britain's National Health Service (NHS) has limited the use of puberty-blocking drugs to children enrolled in clinical trials only, citing a lack of evidence to support their safety or clinical effectiveness as a routinely available treatment. The move comes as the NHS's pediatric gender services struggle to keep up with soaring demand. Other countries, including Finland, Sweden, Norway, and France, have also limited gender-related medical treatments for young people. The NHS will start a clinical trial for all children receiving puberty blockers from the health service, which it expects will begin enrollment in 2024.